Literature DB >> 25489019

Respiratory syncytial virus-associated mortality in hospitalized infants and young children.

Carrie L Byington1, Jacob Wilkes2, Kent Korgenski2, Xiaoming Sheng3.   

Abstract

BACKGROUND AND
OBJECTIVE: Respiratory syncytial virus (RSV) is a common cause of pediatric hospitalization, but the mortality rate and estimated annual deaths are based on decades-old data. Our objective was to describe contemporary RSV-associated mortality in hospitalized infants and children aged <2 years.
METHODS: We queried the Healthcare Cost and Utilization Project Kids' Inpatient Database (KID) for 2000, 2003, 2006, and 2009 and the Pediatric Health Information System (PHIS) administrative data from 2000 to 2011 for hospitalizations with International Classification of Diseases, Ninth Revision, Clinical Modification diagnosis codes for RSV infection and mortality.
RESULTS: The KID data sets identified 607 937 RSV-associated admissions and 550 deaths (9.0 deaths/10 000 admissions). The PHIS data set identified 264 721 RSV-associated admissions and 671 deaths (25.4 deaths/10 000 admissions) (P < .001 compared with the KID data set). The 2009 KID data set estimated 42.0 annual deaths (3.0 deaths/10 000 admissions) for those with a primary diagnosis of RSV. The PHIS data set identified 259 deaths with a primary diagnosis of RSV, with mortality rates peaking at 14.0/10 000 admissions in 2002 and 2003 and decreasing to 4.0/10 000 patients by 2011 (odds ratio: 0.27 [95% confidence interval: 0.14-0.52]). The majority of deaths in both the KID and PHIS data sets occurred in infants with complex chronic conditions and in those with other acute conditions such as sepsis that could have contributed to their deaths.
CONCLUSIONS: Deaths associated with RSV are uncommon in the 21st century. Children with complex chronic conditions account for the majority of deaths, and the relative contribution of RSV infection to their deaths is unclear.
Copyright © 2015 by the American Academy of Pediatrics.

Entities:  

Keywords:  RSV; epidemiology; mortality

Mesh:

Year:  2014        PMID: 25489019      PMCID: PMC4279071          DOI: 10.1542/peds.2014-2151

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  22 in total

1.  Interfacility transfers of noncritically ill children to academic pediatric emergency departments.

Authors:  Joyce Li; Michael C Monuteaux; Richard G Bachur
Journal:  Pediatrics       Date:  2012-06-04       Impact factor: 7.124

2.  Mortality and neonatal morbidity among infants 501 to 1500 grams from 2000 to 2009.

Authors:  Jeffrey D Horbar; Joseph H Carpenter; Gary J Badger; Michael J Kenny; Roger F Soll; Kate A Morrow; Jeffrey S Buzas
Journal:  Pediatrics       Date:  2012-05-21       Impact factor: 7.124

3.  Using a pediatric database to drive quality improvement.

Authors:  Kory Kittle; Kelsi Currier; Lorna Dyk; Kurt Newman
Journal:  Semin Pediatr Surg       Date:  2002-02       Impact factor: 2.754

4.  Appropriateness of age thresholds for respiratory syncytial virus immunoprophylaxis in moderate-preterm infants: a cohort study.

Authors:  Almut G Winterstein; Caitlin A Knox; Paul Kubilis; Christian Hampp
Journal:  JAMA Pediatr       Date:  2013-12       Impact factor: 16.193

Review 5.  Epidemiology and prevention of respiratory syncytial virus infections among infants and young children.

Authors:  Gayle Fischer Langley; Larry J Anderson
Journal:  Pediatr Infect Dis J       Date:  2011-06       Impact factor: 2.129

6.  Deaths among children less than two years of age receiving palivizumab: an analysis of comorbidities.

Authors:  Aparna K Mohan; M Miles Braun; Susan Ellenberg; Judith Hedje; Timothy R Coté
Journal:  Pediatr Infect Dis J       Date:  2004-04       Impact factor: 2.129

7.  Risk of primary infection and reinfection with respiratory syncytial virus.

Authors:  W P Glezen; L H Taber; A L Frank; J A Kasel
Journal:  Am J Dis Child       Date:  1986-06

8.  Inpatient growth and resource use in 28 children's hospitals: a longitudinal, multi-institutional study.

Authors:  Jay G Berry; Matt Hall; David E Hall; Dennis Z Kuo; Eyal Cohen; Rishi Agrawal; Kenneth D Mandl; Holly Clifton; John Neff
Journal:  JAMA Pediatr       Date:  2013-02       Impact factor: 16.193

Review 9.  Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children.

Authors:  Tea Andabaka; Jason W Nickerson; Maria Ximena Rojas-Reyes; Juan David Rueda; Vesna Bacic Vrca; Bruno Barsic
Journal:  Cochrane Database Syst Rev       Date:  2013-04-30

10.  Multiple viral respiratory pathogens in children with bronchiolitis.

Authors:  Hilary E Stempel; Emily T Martin; Jane Kuypers; Janet A Englund; Danielle M Zerr
Journal:  Acta Paediatr       Date:  2008-09-09       Impact factor: 2.299

View more
  61 in total

1.  Letters to the Editor.

Authors:  I Mitchell; B Paes; K Lanctot; Rupesh Chawla; Aaron Chiu; Marianna Mitchell; Cecil Ojah; April Price; Sandra Seigel; Amanda Symington
Journal:  Paediatr Child Health       Date:  2015 Nov-Dec       Impact factor: 2.253

Review 2.  Vaccine Design Informed by Virus-Induced Immunity.

Authors:  Rhiannon R Penkert; Jane S Hankins; Neal S Young; Julia L Hurwitz
Journal:  Viral Immunol       Date:  2020-05-05       Impact factor: 2.257

Review 3.  Ongoing developments in RSV prophylaxis: a clinician's analysis.

Authors:  Fariba Rezaee; Debra T Linfield; Terri J Harford; Giovanni Piedimonte
Journal:  Curr Opin Virol       Date:  2017-05-10       Impact factor: 7.090

4.  Epidemiology of Children With Multiple Complex Chronic Conditions in a Mixed Urban-Rural US Community.

Authors:  Kara A Bjur; Chung-Il Wi; Euijung Ryu; Sheri S Crow; Katherine S King; Young J Juhn
Journal:  Hosp Pediatr       Date:  2019-04

5.  Palivizumab Prophylaxis for Healthy Preterm Infants: More Data Supporting American Academy of Pediatrics Guidelines.

Authors:  Carrie L Byington; Flor M Munoz
Journal:  Pediatrics       Date:  2016-07-18       Impact factor: 7.124

6.  Deprivation and mortality related to pediatric respiratory tract infection: a cohort study in 3 high-income jurisdictions.

Authors:  Maximiliane L Verfürden; Tiffany Fitzpatrick; Laura Holder; Ania Zylbersztejn; Laura Rosella; Ruth Gilbert; Astrid Guttmann; Pia Hardelid
Journal:  CMAJ Open       Date:  2020-04-28

7.  Incidence of Hospitalization for Vaccine-Preventable Infections in Children Following Solid Organ Transplant and Associated Morbidity, Mortality, and Costs.

Authors:  Amy G Feldman; Brenda L Beaty; Donna Curtis; Elizabeth Juarez-Colunga; Allison Kempe
Journal:  JAMA Pediatr       Date:  2019-03-01       Impact factor: 16.193

8.  Identifying Gaps in Respiratory Syncytial Virus Disease Epidemiology in the United States Prior to the Introduction of Vaccines.

Authors:  Lindsay Kim; Brian Rha; Jon S Abramson; Larry J Anderson; Carrie L Byington; Grace L Chen; John DeVincenzo; Kathryn M Edwards; Janet A Englund; Ann R Falsey; Marie R Griffin; Ruth A Karron; Karen G Martin; H Cody Meissner; Flor M Munoz; Andrew T Pavia; Pedro A Piedra; William Schaffner; Eric A F Simões; Rosalyn Singleton; H Keipp Talbot; Edward E Walsh; Jane R Zucker; Susan I Gerber
Journal:  Clin Infect Dis       Date:  2017-09-15       Impact factor: 9.079

9.  Robust Cytokine and Chemokine Response in Nasopharyngeal Secretions: Association With Decreased Severity in Children With Physician Diagnosed Bronchiolitis.

Authors:  Erin G Nicholson; Chelsea Schlegel; Roberto P Garofalo; Reena Mehta; Margaret Scheffler; Minghua Mei; Pedro A Piedra
Journal:  J Infect Dis       Date:  2016-05-18       Impact factor: 5.226

10.  Comparison of Intravenous Palivizumab and Standard of Care for Treatment of Respiratory Syncytial Virus Infection in Mechanically Ventilated Pediatric Patients.

Authors:  Brady J Helmink; Carolyn E Ragsdale; Evan J Peterson; Kathryn G Merkel
Journal:  J Pediatr Pharmacol Ther       Date:  2016 Mar-Apr
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.